Flexion Therapeutics (FLXN) Upgraded to Hold by BidaskClub

Flexion Therapeutics (NASDAQ:FLXN) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.

Several other analysts have also issued reports on FLXN. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Berenberg Bank initiated coverage on shares of Flexion Therapeutics in a research report on Thursday, February 1st. They issued a “buy” rating and a $42.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (down previously from $37.00) on shares of Flexion Therapeutics in a research report on Friday, March 9th. Finally, Wells Fargo set a $39.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a research report on Tuesday, April 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $99.00.

Shares of NASDAQ FLXN opened at $26.56 on Friday. Flexion Therapeutics has a 52-week low of $16.51 and a 52-week high of $32.25. The stock has a market capitalization of $921.68, a PE ratio of -6.38 and a beta of 0.83. The company has a current ratio of 13.02, a quick ratio of 12.96 and a debt-to-equity ratio of 0.58.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.27). The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $1.29 million. research analysts predict that Flexion Therapeutics will post -5.18 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. Wells Fargo & Company MN boosted its position in Flexion Therapeutics by 1,024.1% during the fourth quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock worth $42,742,000 after acquiring an additional 1,555,093 shares during the last quarter. BlackRock Inc. boosted its position in Flexion Therapeutics by 17.4% during the fourth quarter. BlackRock Inc. now owns 2,650,986 shares of the specialty pharmaceutical company’s stock worth $66,381,000 after acquiring an additional 392,055 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Flexion Therapeutics during the fourth quarter worth about $7,712,000. Ardsley Advisory Partners boosted its position in Flexion Therapeutics by 137.1% during the fourth quarter. Ardsley Advisory Partners now owns 415,000 shares of the specialty pharmaceutical company’s stock worth $10,392,000 after acquiring an additional 240,000 shares during the last quarter. Finally, American Financial Group Inc. acquired a new position in Flexion Therapeutics during the fourth quarter worth about $5,280,000. Hedge funds and other institutional investors own 94.15% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply